OrthoPediatrics (NASDAQ:KIDS) Director David Pelizzon Sells 16,300 Shares of Stock

OrthoPediatrics Corp. (NASDAQ:KIDS) Director David Pelizzon sold 16,300 shares of the stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $24.74, for a total transaction of $403,262.00. Following the completion of the sale, the director owned 6,881,464 shares of the company’s stock, valued at $170,247,419.36. This trade represents a 0.24% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

OrthoPediatrics Trading Down 1.9%

KIDS opened at $24.03 on Thursday. The company has a debt-to-equity ratio of 0.28, a current ratio of 4.78 and a quick ratio of 2.17. The company’s 50 day simple moving average is $21.23 and its two-hundred day simple moving average is $18.58. OrthoPediatrics Corp. has a 1-year low of $14.42 and a 1-year high of $26.74. The firm has a market capitalization of $627.42 million, a price-to-earnings ratio of -14.30 and a beta of 0.98.

OrthoPediatrics (NASDAQ:KIDS) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.04. OrthoPediatrics had a negative return on equity of 8.10% and a negative net margin of 15.72%.The business had revenue of $70.51 million during the quarter, compared to analyst estimates of $68.21 million. Analysts expect that OrthoPediatrics Corp. will post -1.14 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have issued reports on KIDS. Weiss Ratings raised OrthoPediatrics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, August 5th. Piper Sandler reiterated an “overweight” rating and set a $25.00 price target (up from $22.00) on shares of OrthoPediatrics in a report on Wednesday, August 5th. TD Cowen reissued a “buy” rating on shares of OrthoPediatrics in a research report on Monday, June 15th. Needham & Company LLC upped their price objective on shares of OrthoPediatrics from $30.00 to $35.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. Finally, Truist Financial set a $22.00 price objective on shares of OrthoPediatrics in a research report on Wednesday, August 5th. Nine investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $26.44.

More OrthoPediatrics News

Here are the key news stories impacting OrthoPediatrics this week:

• Positive Sentiment: OrthoPediatrics completed the full U.S. commercial launch of its 3P™ Pediatric Plating Platform® Hip System after more than 350 successful implantations during a limited release. The company said the system addresses pediatric hip trauma and deformities, improves fixation and surgical workflow, and is the first of several planned systems in a broader plating portfolio. The launch provides a potential long-term revenue and market-share opportunity, although the company did not provide specific financial guidance. OrthoPediatrics Announces Full Commercial Launch of 3P Pediatric Plating Platform Hip System
• Neutral Sentiment: Reported short interest was listed as zero shares with a zero-day short-interest ratio. However, the filing data also showed an invalid “NaN” change, making the statistic unreliable and providing little usable insight into potential short-selling pressure.
• Negative Sentiment: Director David R. Pelizzon and major shareholder entities associated with Squadron Capital and Jennifer N. Pritzker reported sales totaling 38,300 shares for approximately $943,302 across August 24–26, at prices ranging from $24.28 to $25.75. The transactions reduced the reported position by only about 0.56%, leaving ownership of roughly 6.86 million shares, so the sales appear relatively small compared with the remaining stake. Nevertheless, repeated insider selling can weigh on sentiment, particularly with KIDS trading near its 52-week high. SEC insider transaction filing

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Russell Investments Group Ltd. increased its stake in OrthoPediatrics by 433.1% during the third quarter. Russell Investments Group Ltd. now owns 1,402 shares of the company’s stock worth $26,000 after acquiring an additional 1,139 shares during the last quarter. Legal & General Group Plc purchased a new stake in OrthoPediatrics in the second quarter valued at $34,000. Northwestern Mutual Wealth Management Co. lifted its stake in shares of OrthoPediatrics by 5,226.5% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 2,610 shares of the company’s stock valued at $46,000 after purchasing an additional 2,561 shares during the last quarter. Caption Management LLC purchased a new position in shares of OrthoPediatrics during the 3rd quarter worth $54,000. Finally, BNP Paribas Financial Markets grew its holdings in shares of OrthoPediatrics by 60.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 3,288 shares of the company’s stock worth $61,000 after purchasing an additional 1,235 shares during the period. 69.05% of the stock is currently owned by hedge funds and other institutional investors.

OrthoPediatrics Company Profile

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.